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Abstract:
Objectives:
Assess  outcomes  along  the  care  continuum for  HIV-infected  people  who  inject  drugs  (PWID),  by  type  of  facility  and  stage  of
infection at diagnosis.
Methods:
Data reported by 28 jurisdictions to the National HIV Surveillance System by December 2014 were used to identify PWID aged ≥13
years,  diagnosed  with  HIV  infection  before  December  31,  2013.  Analyses  used  the  CDC  definition  of  linkage  to  care  (LTC),
retention in care (RIC), and viral suppression (VS), and are stratified by age, sex, race/ethnicity, and type of facility and stage of HIV
infection at diagnosis.
Results:
Of 1,409 PWID diagnosed with HIV in 2013, 1,116 (79.2%) were LTC with the lowest percentages among males (78.4%); blacks
(77.5%) ages 13-24 years (69.0%); those diagnosed in early stage infection (71.6%); and at screening, diagnostic, or referral agencies
(60.0%).  Of  80,958  PWID  living  with  HIV  in  2012,  40,234  (49.7%)  were  RIC  and  34,665  (42.8%)  achieved  VS.  The  lowest
percentages for RIC and VS were among males (47.1% and 41.3% respectively); those diagnosed with late stage disease (47.1% and
42.4%); and young people. Whites had the lowest RIC (47.0%) while blacks had the lowest VS (41.1%).
Conclusion:
Enhanced LTC activities are needed for PWID diagnosed at screening, diagnostic or referral agencies versus those diagnosed at
inpatient or outpatient settings, especially among young people and blacks diagnosed in early stage infection. Less than half of PWID
are retained in care or reach viral suppression indicating the need for continued engagement and return to care activities over the long
term.
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INTRODUCTION
The National HIV/AIDS Strategy for the United States (NHAS) defines four primary goals: (1) reducing new human
immunodeficiency virus (HIV) infections; (2) increasing access to care and improving health  outcomes for people
 living with  HIV; (3) reducing  HIV-related  disparities  and health  inequities;  and (4)  achieving a more  coordinated
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national response to the HIV epidemic [1]. While people who inject drugs (PWID) make up a relatively small share of
the U.S. population, their risk of HIV infection is disproportionately high [2]. In 2010, there were more than 6.6 million
people aged 13 years and older who had injected drugs during their lifetime and more than 188,000 who were infected
with HIV [3, 4].
While new diagnoses of HIV infection among PWID declined from an estimated 6,004 in 2002 to an estimated
1,795 in 2011 (a 70% decrease) [5] and the number of people living with HIV infection attributed to injection-drug use
(IDU) declined from 143,500 to 140,700 from 2008 to 2010 [6], continued vigilance is needed to detect PWID who are
infected. In 2013 IDU was the third most commonly reported risk factor for HIV infection in the United States after
male-to-male sexual contact and heterosexual contact, and IDU was the only known risk factor for an estimated 6.6% of
HIV infection diagnoses (5.1% of males and 12.4% of females) [7]. For both male and female PWID almost half of
HIV infections in 2013 were among blacks/African Americans. Among male PWID, Hispanics/Latinos and whites each
accounted for just under 25% of HIV diagnoses, while among females whites accounted for 34% and Hispanics/Latinos
for 15% [7].
The NHAS recommends engagement in care and integration of services for HIV testing and treatment provided by
medical professionals, and mental health and substance abuse agencies and practitioners [7]. Specifically, to address the
increased risk of PWID contracting HIV infection the NHAS recommends the development of evidence-based HIV
prevention  recommendations  and  voluntary  routine  testing  at  substance  abuse  and  mental  health  clinics.  However,
recent surveys found that three of four PWID reported not participating in a HIV behavioral prevention program and
half  reported  not  having  been  tested  for  HIV  in  the  past  12  months  [8,  9].  Among  PWID  attending  one  of  five
community-based substance abuse treatment  programs that  offered free  HIV testing,  nearly  one-third  had not  been
tested  in  the  prior  12  months  [10].  Data  from  the  Substance  Abuse  and  Mental  Health  Services  Administration
(SAMHSA)  indicate  that  less  than  50%  of  substance  abuse  treatment  programs  provide  on-site  infectious  disease
screening  and  that  inpatient  facilities  were  more  likely  than  non-inpatient  facilities  to  offer  such  tests  [11].
Notwithstanding  these  challenges,  PWID  have  the  lowest  percentage  of  undiagnosed  HIV  infection  [4].
HIV  diagnosis  is  the  entry  point  to  the  continuum  of  HIV  care,  and  the  2013  Presidential  Continuum  of  Care
Initiative recommended identification of gaps in the other essential steps of the continuum, including linkage to care,
retention in care, and antiretroviral (ARV) treatment to achieve the ultimate goal of viral suppression [12]. One study of
outpatients  presenting  for  initial  HIV  primary  care  found  that  the  mean  duration  between  HIV  infection  and
presentation for HIV-related medical care is as long as eight years [13]. Torian (2008) found that testing at a community
testing site or health department and IDU were risk factors for failure to link to care within 3 months of diagnosis [14].
PWID  infected  with  HIV  may  also  have  challenges  remaining  engaged  in  care  or  achieve  viral  suppression.  This
analysis assessed linkage to and retention in care and viral suppression among people classified by the National HIV
Surveillance System (NHSS) as having the single risk factor of injection-drug use. Analyses included examination of
the characteristics of persons diagnosed with HIV linked to care, retained in care, and virally suppressed, linkage to care
by type of facility at diagnosis and retention in care and viral suppression by stage of disease at diagnosis. This is the
first  study  we  know  of  to  look  at  these  components  of  the  continuum  of  care  for  PWID  using  surveillance  data,
including place and stage of diagnosis for PWID infected with HIV.
METHODS
All  data  from  the  National  HIV  Surveillance  System  (NHSS),  described  elsewhere  [15],  reported  to  the  CDC
through December 2014 were used to identify cases of HIV infection meeting the CDC case definition [16] among
PWID aged 13 years and older who had received a diagnosis of HIV infection before December 31, 2013 and whose
residence at diagnosis was one of 28 jurisdictions. Data were included from jurisdictions that met three criteria:
the jurisdiction’s laws/regulations required the reporting of all CD4 and viral load results to the state/city health1.
department;
laboratories that perform HIV-related testing for the areas had reported a minimum of 95% of HIV-related test2.
results to the jurisdiction health department; and
by December 31, 2014, the jurisdiction had reported (to CDC) at least 95% of all CD4 and viral load test results3.
received from January 2011 through September 2013.
The  28  jurisdictions  that  met  these  criteria  were  Alabama,  Alaska,  Arkansas,  California,  District  of  Columbia,
Hawaii,  Illinois,  Indiana, Iowa, Louisiana, Maine, Maryland, Michigan, Missouri,  Nebraska, New Hampshire, New
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York,  North  Dakota,  Oregon,  South  Carolina,  South  Dakota,  Tennessee,  Texas,  Utah,  Virginia,  Washington,  West
Virginia, and Wisconsin.
The linkage to care analysis was limited to PWID who were diagnosed with HIV infection during 2013. Linkage to
care was defined as ≥1 CD4 or VL test within 3 months of diagnosis. The retention in care and viral load suppression
analysis included people who were diagnosed before 2012 and were not known to be deceased on December 31, 2012.
Data from 2012 were selected to allow for at least 18 months to report both HIV-infected people and deaths. Retention
in  care  was  defined  as  ≥2  CD4 or  VL tests  performed at  least  3  months  apart  during  2012.  Viral  suppression  was
defined as a viral load test result of <200 copies/mL or, if the quantitative value was missing, a test interpretation value
of “undetectable”, at the time of the most recent viral load test during 2012. Laboratory results with no month and year
of  specimen  collection  were  excluded  from  the  analysis.  If  there  were  two  test  results  for  the  same  month  with
conflicting  viral  suppression  results,  the  test  result  that  indicated  lack  of  viral  suppression  was  used.  In  addition,
laboratory tests with a blank result and tests with specimen collection dates prior to the date of HIV infection diagnosis
were excluded.
Analyses were adjusted for unknown transmission category [7]. Data were stratified by age group (13-24, 25-34,
35-44, 45-54, ≥55), sex, race/ethnicity (black/African American, white, Hispanic/Latino, other), and type of facility at
diagnosis  (inpatient,  outpatient,  screening/diagnostic/referral  agency,  and  other).  Stage  of  disease  at  diagnosis  was
categorized as early stage infection (defined as the absence of an HIV Stage 3 [AIDS] diagnosis within 3 months of an
HIV diagnosis) or late stage infection (defined as the presence of a confirmed HIV Stage 3 [AIDS] diagnosis within 3
month of an HIV diagnosis). All analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Of the 1,409 PWID with HIV infection diagnosed during 2013 in the 28 jurisdictions, 1,106 (79.2%) were linked to
care ≤3 months after  HIV diagnosis  (Table 1).  The estimated percentage of males and females linked to care were
similar  (78.4% and  80.4%,  respectively).  African  Americans/blacks  (hereafter  referred  to  as  blacks)  (77.5%)  were
linked to care less often than whites (81.6%) and Hispanic/Latinos (81.4%) as were those in younger age groups (e.g.,
linkage to care 69.0% among those aged 13-24 years vs. 81.8% among those aged 45-54years). The percentage linked
to care was higher among those diagnosed in late-stage infection (98.1%) compared with those not diagnosed in late-
stage infection (71.6%).
Table 1. Linkage to HIV care among people aged ≥13 years who inject drugsa and had their HIV infection diagnose during
2013, by selected characteristics-National HIV Surveillance System, 28 jurisdictionsb, United States.
Characteristic Number of HIV diagnoses Linked to carec
No. No. (%)
Sex
 Male 842 661 78.4
 Female 567 456 80.4
Race/ethnicity
 Black/African American 631 489 77.5
  Hispanic/Latinod 301 245 81.4
 White 391 319 81.6
 Othere 86 63 73.6
Age group at diagnosis (yrs)
 13-24 131 91 69.0
  25-34 315 244 77.5
 35-44 306 249 81.4
 45-54 384 314 81.8
 55+ 272 218 80.1
Stage at diagnosis
 HIV infection stage 1, 2 or unknown 1003 718 71.6
 HIV infection stage 3 [AIDS] 406 399 98.1
Type of facility at diagnosis
 Inpatient 409 353 86.3
 Outpatient 468 377 80.4
130   The Open AIDS Journal, 2016, Volume 10 Karch et al.
Characteristic Number of HIV diagnoses Linked to carec
No. No. (%)
 Screening, diagnostic, referral agencyf 124 74 60.0
 Other/unknown 408 313 76.6
Totalg 1,409 1,116 79.2
Abbreviation: HIV = human immunodeficiency virus.
aData statistically adjusted to account for missing transmission categories.
bJurisdictions include Alabama, Alaska, Arkansas, California, District of Columbia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland,
Michigan, Missouri, Nebraska, New Hampshire, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia,
Washington, West Virginia, and Wisconsin.
cDefined as one or more CD4+ T-lymphocyte or viral load test within 3 months after HIV diagnosis.
dHispanic/Latino can be of any race.
eIncludes American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islander, and multiple races.
fExamples include blood banks, family planning clinics, sexually transmitted disease clinics and case management agencies.
gEstimates might not sum to total.
Linkage to care varied depending on the type of care at time of diagnosis (inpatient, 86.3%; outpatient, 80.4%; and
screening,  diagnostic  or  referral  agency  (SDR),  60.0%)  (Table  2).  This  pattern  was  observed  regardless  of  sex,
race/ethnicity, age at diagnosis, or stage at diagnosis with the greatest absolute difference between inpatient and SDR
agencies among those aged 13-24 years (absolute difference 41.9 percentage points), blacks (31.1 percentage points),
and  females  (27.1  percentage  points).  Males  and  females  diagnosed  at  inpatient  (males=84.5%,  females=89.1%),
outpatient (males=79.0%, females=81.9%) and SDR (males=58.2%, females=62.0%) facilities were linked to care with
similar frequency. Regardless of place of diagnosis, PWID with late stage disease were more likely to be linked to care
within three months after care.
Of  the  80,958 PWID with  HIV infection diagnosed before  2012 and alive  on December  31,  2012,  49.7% were
retained  in  care  and  42.8% achieved  viral  suppression  (Table  3).  Females  were  both  retained  in  care  (53.8%)  and
achieved viral suppression (45.2%) more often than males (47.1% and 41.3%, respectively). Whites were slightly less
likely to be retained in care (47.0%) when compared to other race/ethnicity groups but more likely to achieve viral
suppression (45.5%) (Table 3). By age group, both retention in care and viral suppression increased with age (retention
in care: 13-24 years, 42.7% and 55 years and older, 49.8%; and viral suppression: 13-24 years, 30.6% and 55 years and
older, 45.2%). Retention in care among PWID with infection diagnosed in late stage (47.1%) was lower than among
those not with late stage disease (50.6%); viral suppression was similar among PWID with infection diagnosed late
compared with those without late stage disease (42.4% and 43.0% respectively).
Table 2. Linkage to care by facility at HIV diagnosis among people who inject drugsa and had their HIV infection diagnosed
during 2013, by selected characteristics-National HIV Surveillance System, 28 jurisdictionsb, United States.
Type of facility at diagnosis
Inpatient Outpatient Screening, diagnostic, referralagencyc
Total Linked to Cared Total Linked to Cared Total Linked to Cared
No. No. (%) No. No. (%) No. No. (%)
Characteristic
 Sex
 Male 245 207 84.5 246 195 79.0 67 39 58.2
 Female 163 146 89.1 222 182 81.9 57 35 62.0
Race/ethnicity
  Black/African American 184 158 85.6 201 161 80.3 48 26 54.5
  Hispanic/Latinoe 100 87 87.4 89 70 78.5 22 13 59.1
 White 96 86 89.2 149 124 83.0 48 32 66.6
 Otherf 29 22 77.5 29 21 72.8 6 3 53.6
Age group at diagnosis (yrs)
 13-24 25 24 93.3 42 27 64.4 25 13 51.4
 25-34 68 58 86.1 103 84 81.2 47 28 60.5
 35-44 90 80 88.9 96 81 84.0 28 19 69.2
  45-54 117 101 86.4 139 114 82.0 18 11 60.6
  55+ 109 90 82.6 88 71 80.7 6 3 46.6
(Table ) contd.....
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Type of facility at diagnosis
Inpatient Outpatient Screening, diagnostic, referralagencyc
Total Linked to Cared Total Linked to Cared Total Linked to Cared
Stage at diagnosis
 HIV infection stage 1, 2 218 167 76.3 358 269 75.1 112 62 55.7
or unknown
  HIV infection stage 3 [AIDS]) 190 186 97.8 110 108 97.5 12 12 100
Totalg 409 353 86.3 468 377 80.4 124 74 60.0
Abbreviation: HIV = human immunodeficiency virus.
aData statistically adjusted to account for missing transmission categories.
bJurisdictions include Alabama, Alaska, Arkansas, California, District of Columbia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland,
Michigan, Missouri, Nebraska, New Hampshire, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia,
Washington, West Virginia, and Wisconsin.
cExamples include blood banks, family planning clinics, sexually transmitted disease clinics and case management agencies.
dDefined as one or more CD4+ T-lymphocyte or viral load test within 3 months after diagnosis.
eHispanic/Latino can be of any race.
fIncludes American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islander, and multiple races.
gEstimates might not sum to total.
Table 3. Retention in care and viral suppression among people aged ≥13 years who inject drugsa and had their HIV infection
diagnosed before 2012 and were alive on December 31, 2012, by selected characteristics-National HIV Surveillance System,
28 jurisdictionsb, United States.
Number of HIV diagnoses Retained in carec Viral suppressiond
No. No. (%) No. (%)
Characteristic
 Sex
 Male 49,537 23,324 47.1 20,474 41.3
Female 31,421 16,910 53.8 14,191 45.2
Race/ethnicity
  Black/African American 42,868 21,021 49.0 17,630 41.1
  Hispanic/Latinoe 19,695 9,869 50.1 8,384 42.6
 White 14,699 6,905 47.0 6,548 44.5
  Otherf 3,696 2,438 66.0 2,103 56.9
Age group at end of 2011 (yrs)
 13-24 634 270 42.7 194 30.6
 25-34 4,887 2,122 43.4 1,672 34.2
  35-44 15,067 7,151 47.5 5,865 38.9
 45-54 33,375 17,237 51.6 14,743 44.2
 ≥55 26,995 13,453 49.8 12,192 45.2
Stage at diagnosis
 HIV infection stage 1, 2 or unknown 59,333 30,045 50.6 25,502 43.0
  HIV infection stage 3 [AIDS] 21,624 10,189 47.1 9,163 42.4
Totalg 80,957 40,234 49.7 34,665 42.8
Abbreviation: HIV = human immunodeficiency virus.
aData statistically adjusted to account for missing transmission categories.
bJurisdictions include Alabama, Alaska, Arkansas, California, District of Columbia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland,
Michigan, Missouri, Nebraska, New Hampshire, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia,
Washington, West Virginia, and Wisconsin.
cDefined as two or more CD4+ T-lymphocyte or viral load tests at least 3 months apart during 2012.
dDefined as a viral load result of ≤200 copies/mL at the most recent viral load test during 2012.
eHispanic/Latino can be of any race.
fIncludes American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islander, and multiple races.
gEstimates might not sum to total.
The  higher  percentage  of  retention  in  care  among  PWID  with  infection  diagnosed  during  early  stage  when
compared to those with late stage disease (Table 4) was also generally true by sex and age. By race/ethnicity, however,
(Table ) contd.....
132   The Open AIDS Journal, 2016, Volume 10 Karch et al.
differences by disease severity at diagnosis were small except for Hispanics/Latinos. Hispanic/Latino PWID with HIV
diagnosed late were less likely to be retained in care or have a suppressed viral load. By age, PWID aged <45 years and
with HIV diagnosed late more commonly had a suppressed viral load compared with those without late stage disease;
however, differences were small for older persons.
Table 4. Retention in care and viral suppression by stage at HIV diagnosis among people aged ≥13 years who inject drugsa,
and  had  their  HIV  infection  diagnosed  before  2012,  and  were  alive  on  December  31,  2012,  by  selected  characteristics-
National HIV Surveillance System, 28 jurisdictionsb, United States.
Diagnosed during stage 1, 2, or unknown Diagnosed during stage 3 [AIDS]
Total Retained in carec
Achieved Viral
Suppressiond Total Retained in care
c Achieved viral
suppressiond
No. No. (%) No. (%) No. No. (%) No. (%)
Characteristic
 Sex
 Male 34,845 16,750 48.1 14,481 41.6 14,692 6,574 44.7 5,993 40.8
 Female 24,488 13,296 54.3 11,021 45.0 6,932 3,614 52.1 3,170 45.7
Race/ethnicity
 Black/African American 31,594 15,620 49.4 12,952 41.0 11,273 5,401 47.9 4,678 41.5
 Hispanic/Latinoe 14,072 7,476 53.1 6,213 44.2 5,623 2,393 42.6 2,171 38.6
 White 10,871 5,098 46.9 4,769 43.9 3,828 1,807 47.2 1,779 46.5
 Otherf 2,796 1,851 66.2 1,569 56.1 900 587 65.3 535 59.4
Age group at end of 2011 (yrs)
 13-24 571 239 41.8 168 29.4 63 32 50.5 26 40.9
  25-34 4,200 1,786 42.5 1,387 33.0 688 336 48.8 285 41.5
  35-44 11,750 5,615 47.8 4,503 38.3 3,316 1,536 46.3 1,362 41.1
 45-54 24,549 12,900 52.5 10,909 44.4 8,826 4,337 49.1 3,834 43.4
  ≥55 18,263 9,505 52.0 8,536 46.7 8,732 3,948 45.2 3,656 41.9
Totalg 59,333 30,045 50.6 25,502 43.0 21,624 10,189 47.1 9,163 42.4
Abbreviation: HIV = human immunodeficiency virus.
aData statistically adjusted to account for missing transmission categories.
bJurisdictions include Alabama, Alaska, Arkansas, California, District of Columbia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland,
Michigan, Missouri, Nebraska, New Hampshire, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia,
Washington, West Virginia, and Wisconsin.
cDefined as two or more CD4+ T-lymphocyte or viral load tests at least 3 months apart during 2012.
dDefined as a viral load result of ≤200 copies/mL at the most recent viral load test during 2012.
eHispanic/Latino can be of any race.
fIncludes American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islander, and multiple races.
gEstimates might not sum to total.
DISCUSSION/IMPLICATIONS
This study explores care and treatment among people with HIV infection, reported to the NHSS by December 31,
2014, whose only risk factor was injection drug use, by type of facility and stage of infection at diagnosis. While three
of four PWID were linked to HIV care, less than half were retained in care or achieved viral suppression; slightly fewer
than care and viral suppression among MSM [4]. Substance use has been linked with HIV infection since the beginning
of the epidemic. In people already infected with HIV, substance abuse can impact overall health and accelerate disease
progression and mortality [17]. Some studies have found that due to psycho-social instability and co-morbid addictions
such  as  alcohol  abuse  PWID may  be  less  willing  to  start  or  adhere  to  ARV medications  than  persons  who  do  not
actively inject drugs [17].While measuring adherence can be challenging [18], another study found that PWID were
over  three  times  as  likely  (OR  3.49;  95%  CI,  1.45-8.40)  to  use  ARV  when  enrolled  in  drug  or  alcohol  treatment
programs [19]. Comprehensive prevention strategies that address the complex or syndemic interaction of health, social,
and environmental needs of HIV-infected PWID are needed [20 - 23] and should include HIV testing and counseling
and treatment for substance abuse [24].
Similar to other studies, our analysis showed considerable variation in care use between demographic groups. Male
PWID were as  likely to link to care as  female PWID but  were less  likely to receive regular  care and achieve viral
suppression. Whites were linked to care more often than blacks and Hispanic/Latinos; however, whites were least likely
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to be retained in care, although viral suppression was similar for all racial and ethnic groups (range 41.3%-43.7%) with
the exception of the race/ethnicity of “other”. Finally, younger PWID were generally less likely to be linked to and
retained in care and achieve viral suppression than older PWID [4, 25]. Implementing effective interventions among
minorities, males, and youth could improve outcomes for HIV-infected PWID along the continuum of care [24].
In  2010 the  National  HIV/AIDS Strategy established a  target  that  by 2015 the  proportion of  persons  with  HIV
linked to care within 3 months of HIV diagnosis increase to 85% [1]. Our results indicate that in 2013, linkage to care
was still well below this 2015 target for PWID. In comparing our findings to the continuum of care for men who have
sex with men (MSM) [25], we noted that linkage to care among PWID (78.6%) was similar to that for MSM (77.5%).
Retention in care estimate (MSM: 50.9%, PWID: 49.4%) and viral suppression were also similar for PWID (42.6%) and
MSM (42.0%). In 2015 the updated National HIV/AIDS Strategy for the United States renewed that standard through
2020 but reduced the timeframe for linkage to care from three months to one month [26]. Efforts and resources are still
needed to monitor and improve outcomes across the HIV continuum of care for these high-priority populations.
Continued focus on linkage to care is needed for those diagnosed in a screening, diagnostic, or referral agency,
especially when compared to inpatient and outpatient settings, for every sex, race/ethnicity, age, and stage of diagnosis
category assessed. Public clinics that provide these services play an important role in reaching out to people who do not
seek care at traditional health care facilities. In addition to having routine HIV testing available, clinics must consider
approaches to proactive linkage to care [14]. Ideally, clinic staff will assist people with HIV with setting up their first
appointment and provide or refer PWID to substance abuse treatment programs. Likewise, substance abuse treatment
programs could assist by offering on-site infectious disease screening and services for linking people with HIV to care
[11]. Access to HIV counseling, testing, and treatment continues to vary widely across drug treatment programs [27],
creating a missed public health opportunity to get HIV infections among PWID diagnosed and those living with HIV
into care.
More than one in four PWID with HIV had stage 3 [AIDS] HIV infection at the time of diagnosis. Diagnosing HIV
early  in  the  course  of  infection  is  critical  to  allow  prompt  linkage  to  care  and  treatment  to  reduce  morbidity  and
mortality and the potential for the onward transmission of the virus. In addition, diagnosis in the acute stage would
benefit prevention as the high viral load levels found in the acute stage substantially increase the risk of transmission
[28]. Recent studies found that more frequent and expanded HIV testing for PWID would reduce the number of new
infections and be cost effective [29]; however less than half of PWID receive the recommended annual HIV testing
[28]. People diagnosed with stage 3 [AIDS] HIV infection (AIDS) may have symptoms and therefore be more likely to
be prescribed ARV medications. However, our results indicate that care and viral suppression was low even among
PWID with infection diagnosed late.
This study is subject to at least four limitations. First, analysis of NHSS data is limited to 28 jurisdictions (61.4% of
all persons aged ≥13 years living with diagnosed HIV infection at year-end 2012, the most recent data) with complete
reporting of all levels of CD4 and VL test results and may not be representative of all people who inject drugs in the
United States. Second, documentation of the most recent VL might not be indicative of consistent viral suppression in
this population over time. Third, not all people with HIV infection are identified and entered in the NHSS, including
those who are unaware of their HIV infection status (i.e., not yet diagnosed). Fourth, retention in care does not always
mean that people were initiated on ART and thus the percentage of people reaching viral suppression includes both
those initiated on ART and those not initiated on ART.
CONCLUSION
CDC has adopted a high-impact prevention approach to advance the goals of the National HIV/AIDS Strategy by
using a  combination of  scientifically  proven,  cost-effective,  and scalable  interventions  targeted to  PWID and other
populations at greatest risk for HIV infection [24]. Substance abuse treatment programs, syringe services programs, and
community outreach are examples of the behavioral risk reductions and other public health strategies that are critical to
the foundation of reducing HIV transmission between PWID and their sex partners [27].
Increasing the proportion of PWID living with HIV who are receiving care is critical for achieving the goals of the
National  HIV/AIDS  Strategy  to  reduce  new  infections,  improve  health  outcomes,  and  decrease  health  disparities.
Greater access to HIV testing and drug treatment facilities as well as targeted strategies for high-risk groups, such as
minorities, males and youths, may be needed to achieve improvements at each step of the HIV care continuum.
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